Drug
Ezabenlimab clinical trials
Also written BI 754091.
- studies test it
- 23
- open now
- 4
- in phase 3
- 1
- first study started
- 2016
Keep track of what changes. Save the ezabenlimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
23 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 20
- Phase 2
- 2
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 3
Boehringer Ingelheim (18) · Amal Therapeutics (1) · OSE Immunotherapeutics (1) · National Health Research Institutes, Taiwan (1) · Johann Wolfgang Goethe University Hospital (1) · Institut Bergonié (1)
Often tested with
Tested in the same studies.
Pembrolizumab (2) · Brigimadlin (2) · VSV-GP-based Cancer Vaccine VSV-GP154 (1) · Therapeutic Cancer Vaccine ATP150 (1) · Therapeutic Cancer Vaccine ATP152 (1) · Therapeutic Cancer Vaccine ATP162 (1) · Obrixtamig (1) · VSV-GP128 (1)
Studies
Open first, then newest update. How each study uses ezabenlimab is read from its arms, and is right about nine times in ten.
Testing it · 23
- A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)RecruitingPhase 1Boehringer IngelheimNCT05471856Written as Ezabenlimab
- A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced CancerNot yet recruitingPhase 1Boehringer IngelheimNCT07851103Written as ezabenlimab
- A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With EzabenlimabRecruitingPhase 1Boehringer IngelheimNCT07607678Written as Ezabenlimab (BI 754091)
- Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive GlioblastomaRecruitingPhase 1Johann Wolfgang Goethe University HospitalNCT03383978Written as Ezabenlimab
- A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6TerminatedPhase 1Boehringer IngelheimNCT06091930Written as Ezabenlimab
- A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck CancerActive, not recruitingPhase 1Boehringer IngelheimNCT04958239Written as Ezabenlimab
- A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are ToleratedActive, not recruitingPhase 1Boehringer IngelheimNCT05327946Written as ezabenlimab
- A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal AdenocarcinomaActive, not recruitingPhase 1Boehringer IngelheimNCT05846516Written as Ezabenlimab
- A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Active, not recruitingPhase 1Boehringer IngelheimNCT05879978Written as Ezabenlimab
- A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell SurfaceCompletedPhase 1Boehringer IngelheimNCT04752215Written as ezabenlimab
- A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid TumoursCompletedPhase 1Boehringer IngelheimNCT02952248Written as BI 754091
- This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091TerminatedPhase 1Boehringer IngelheimNCT03780725Written as BI 754091
- A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid TumoursCompletedPhase 1Boehringer IngelheimNCT03468426Written as Ezabenlimab
- A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced CancerCompletedPhase 1Boehringer IngelheimNCT03972150Written as BI 754091
- Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid StructuresWithdrawnPhase 2Institut BergoniéNCT06084689Written as Ezabenlimab + BI907828
- A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)CompletedPhase 1Boehringer IngelheimNCT04147234Written as BI 754091
- A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid TumoursCompletedPhase 1OSE ImmunotherapeuticsNCT03990233Written as BI 754091
- A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in SurgeryTerminatedPhase 1Boehringer IngelheimNCT05446129Written as Ezabenlimab
- Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal CancerActive, not recruitingPhase 1Amal TherapeuticsNCT04046445Written as BI 754091
- A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have SpreadTerminatedPhase 1Boehringer IngelheimNCT03166631Written as BI 754091
See all 23 studies that test ezabenlimab →
Given in every arm · 8 — ezabenlimab is usual care beside what is tested
- A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)SuspendedPhase 1Boehringer IngelheimNCT07395258Written as Ezabenlimab
- A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking EzabenlimabActive, not recruitingPhase 1Boehringer IngelheimNCT05068102Written as Ezabenlimab
- A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver CancerCompletedPhase 1Boehringer IngelheimNCT05249426Written as Ezabenlimab
- A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)CompletedPhase 1Boehringer IngelheimNCT03964233Written as ezabenlimab
- Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid TumoursCompletedPhase 2Boehringer IngelheimNCT03697304Written as Ezabenlimab
- This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.CompletedPhase 1Boehringer IngelheimNCT03156114Written as Ezabenlimab
- This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of CancerCompletedEarly Phase 1Boehringer IngelheimNCT03433898Written as Ezabenlimab
- A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal CancerWithdrawnPhase 2Boehringer IngelheimNCT04499352Written as BI 754091
Codes
What other systems call ezabenlimab · ClinicalTrials.gg INT015128
- UNII (FDA) 5V1UI86573EZABENLIMABOne source FDA
- NCI Thesaurus C132252EzabenlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5V1UI86573 | EZABENLIMAB | One source FDA |
| NCI Thesaurus | C132252 | Ezabenlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.